SH Cheng - Life Science and Medicine

45

40

42.5

Xing Kang

Dr

05/10/1992

M9127

Email hidden; Javascript is required.

+6585741500

Level 10, Clinical Science Building 11 Mandalay Road
Singapore
Singapore

As a scientist driven by curiosity and the desire to address pressing challenges in cancer therapeutics, I am eager to participate in the 2025 Hong Kong Laureate Forum. This prestigious platform provides a once-in-a-lifetime opportunity to connect with world-renowned Shaw Laureates, distinguished scientists, and fellow young researchers across disciplines. By immersing myself in this interdisciplinary environment, I aspire to broaden my understanding of global scientific advancements and foster meaningful collaborations.
My research focuses on the role of the gut microbiome in modulating cancer progression and therapy response, particularly in colorectal cancer. The Forum’s emphasis on cross-disciplinary exchange aligns with my belief that the most innovative solutions arise from the intersection of diverse scientific fields. Learning from esteemed experts and sharing my research findings will help me refine my ideas and contribute to advancing cancer treatment strategies.
Beyond academic enrichment, I am inspired by the Forum’s mission to promote scientific excellence and nurture the next generation of researchers. By participating, I aim to gain insights that will shape my future work, inspire others in my field, and contribute to the collective effort to address global health challenges.
I am enthusiastic about the opportunity to contribute to and grow through this event.

Postdoc

Microbiome and colorectal cancer

Nanyang Technological University

Singapore

Open Fund-Young Individual Research Grant (OF-YIRG), 2025
Dr. Barbara Kwok Young Postdoctoral Researcher Travel Grants, CUHK, 2023
APDWF-JGHF Educational Grant, Asian Pacific Digestive Week 2021

My research investigates the gut microbiome’s role in cancer progression and its potential as a therapeutic target. Specifically, I explore how microbial metabolites influence immune responses and therapeutic efficacy in colorectal cancer. One of my key studies identified Roseburia intestinalis as a butyrate producer that enhances anti-PD-1 immunotherapy efficacy by activating cytotoxic CD8+ T cells, significantly improving outcomes in preclinical models. This work highlights the potential of microbiome-based interventions to augment cancer immunotherapy.

Additionally, I investigate host-microbiome interactions in various cancers, focusing on how gut dysbiosis contributes to tumor microenvironment alterations. For example, I have demonstrated that specific probiotic strains, such as Lactococcus lactis, suppress tumorigenesis by restoring gut microbiota balance and producing beneficial metabolites like alpha-mannosidase. These findings suggest a novel avenue for developing microbiota-inspired therapeutics.

My research interests extend to understanding diet’s impact on microbiota composition and its downstream effects on cancer risk and progression. I am also keen on discovering next-generation probiotics that can synergize with existing therapies.

By leveraging multidisciplinary approaches, my aim is to translate microbiome research into clinically relevant strategies, improving outcomes for cancer patients and contributing to the broader field of precision medicine.